



Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS

Regd. Office: 4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar-393002.
Administrative Office: 101, Shiv Shakti Industrial Estate, Andheri-Kurla Rd., Andheri (East), Mumbai -400059.

UNAUDITED FINANCIAL RESULTS [PROVISIONAL] OF QUARTER ENDED 31ST DECEMBER, 2007

(Rs. in Lacs)

		Quarter Ended 31.12.2007 (Unaudited)	Quarter Ended 31.12.2006 (Unaudited)	9 Months Ended 31.12.2007 (Unaudited)	18 Months Ended 31.03.2007 (Audited)
1.	Net Sales/Income from operations	2591.36	3008.62	8300.12	13427.79
2.	Other Income	90.53	29.37	292.76	987.08
3.	Total Expenditure				
	(a) (Increase)/Decrease in Stock in Trade	(193.24)	25.91	(233.24)	(82.82)
	(b) Consumption of Materials	1565.23	1717.99	4748.66	8955.58
	(c) Staff Cost	171.63	167.31	507.12	847.77
	(d) Other Expenditure (Incl. Excise Duty)	775.41	890.23	2343.82	3347.47
		2319.03	2801.44	7366.36	13068.00
4.	Operational Profit / (Loss) before Interest, Depreciation and Taxation	362.86	236.55	1226.52	1346.87
5.	Interest & Finance Cost	168.21	82.46	528.38	874.88
6.	Depreciation	48.10	44.00	134.26	213.19
7.	Profit / (Loss) before Tax (4-5-6)	146.55	110.09	563.88	258.80
8.	Bad Debts/Advances Written off	-	-	-	1,761.56
9.	Loss on Investment	-	-	-	368.00
10.	Earlier Year Taxes	(1.55)	-	(1.55)	(119.20)
	Provision for Tax (FBT)	3.00	1.03	9.00	13.98
11.	Net Profit / (Loss) (7-8-9-10)	145.10	109.06	556.43	(1765.54)
12.	Paid-up Equity Share Capital (Face Value Rs.10/- per Share)	2013.50	1465.00	2013.50	1527.50
	Paid up Pref. Share Capital (Face Value Rs. 100/- per Share)	108.57	108.57	108.57	108.57
13.	Reserves excluding Revaluation Reserve				2,782.70
14.	Earning Per Share on PBT (Rs.) (Basic & Diluted)	0.61	0.74	2.35	(12.53)
15.	Aggregate of Non-promoter Shareholding Number of Shares	16,552,735	11,742,785	16,552,735	11,892,785
	Percentage of Shareholding	82.21	80.16	82.21	77.86

Notes:

1. The above results, were duly considered by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 31st January, 2008.
2. The Company has one Single Segment "Pharmaceuticals".
3. Net sales / Income from operations include Processing Charges of Rs. 327.92 Lacs.
4. During the quarter, the Company has allotted on a preferential basis 36.50 lacs Equity Shares of Rs.10/- each at a premium of Rs. 45/- per share and 22.00 lacs Equity Share Warrants at an exercise price of Rs. 55/- per warrant.
5. The loss/gain on exchange fluctuation on GDR Funds for the current year will be provided at the end of the year.
6. No depreciation has been provided in respect of revalued Assets for Building and Plant & Machinery during the quarter.
7. 1 (one) complaint of Investors received during the quarter has been resolved.
8. Previous period/quarter figures have been regrouped wherever necessary.
9. Audit qualifications in respect of Audited Accounts for 2005-07 and management comments thereon are detailed below:
 - I. The deferment of R & D expenditure of Rs.1,61,14,667/- & GDR Issue expenses of Rs. 91,61,542/- which is not in compliance with Accounting Standard (AS-26). The Company has explained at note No. 15 to the accounts.
 - II. Regarding non-provision of arrears of ex-gratia at Rs.3,66,69,307/-, the matter presently is subjudice.

Place : Mumbai
Dated : 31st January, 2008

For **LYKA LABS LIMITED**
(N. I. GANDHI)
Chairman & Managing Director

PRESSMAN